Clinical Scorecard: Combined Single-Cell and Bulk RNA Sequencing Reveals a Gene Signature Related to Myeloid States for Molecular Classification in Gastric Adenocarcinoma

At a Glance

Key Highlights

• Identification of 32 myeloid state-related prognostic genes (MSRPGs).
• Stratification of STAD patients into three subtypes based on immune infiltration: LI-STAD, MI-STAD, HI-STAD.
• HI-STAD subtype associated with the poorest overall survival.
• Development of a 5-gene prognostic signature for risk assessment.
• Exploratory pharmacogenomic analysis indicating potential subtype-specific therapeutic vulnerabilities.

Guideline-Based Recommendations

Diagnosis

• Utilize molecular classification frameworks for improved patient stratification.

Management

• Consider subtype-specific therapeutic strategies based on myeloid state classification.

Monitoring & Follow-up

• Assess patient prognosis using the identified 5-gene risk model.

Risks

• Patients with HI-STAD subtype exhibit the highest risk of poor outcomes.

Patient & Prescribing Data

Patients with gastric adenocarcinoma undergoing treatment.

Potential associations with drugs like dabrafenib and ruxolitinib based on myeloid state classification.

Clinical Best Practices

• Integrate multi-omics data for comprehensive patient assessment.
• Utilize immunohistochemistry for protein-level validation of molecular classifications.

Related Resources & Content

• Gene Expression Omnibus (GEO)